269 related articles for article (PubMed ID: 27645786)
1. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Pandey K; Ravidas V; Siddiqui NA; Sinha SK; Verma RB; Singh TP; Dhariwal AC; Das Gupta RK; Das P
Am J Trop Med Hyg; 2016 Nov; 95(5):1100-1105. PubMed ID: 27645786
[TBL] [Abstract][Full Text] [Related]
2. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Bhattacharya SK; Sinha PK; Sundar S; Thakur CP; Jha TK; Pandey K; Das VR; Kumar N; Lal C; Verma N; Singh VP; Ranjan A; Verma RB; Anders G; Sindermann H; Ganguly NK
J Infect Dis; 2007 Aug; 196(4):591-8. PubMed ID: 17624846
[TBL] [Abstract][Full Text] [Related]
3. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
4. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
[TBL] [Abstract][Full Text] [Related]
6. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
7. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
9. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
Bhattacharya SK; Jha TK; Sundar S; Thakur CP; Engel J; Sindermann H; Junge K; Karbwang J; Bryceson AD; Berman JD
Clin Infect Dis; 2004 Jan; 38(2):217-21. PubMed ID: 14699453
[TBL] [Abstract][Full Text] [Related]
11. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
[TBL] [Abstract][Full Text] [Related]
12. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
13. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Jha TK; Sundar S; Thakur CP; Bachmann P; Karbwang J; Fischer C; Voss A; Berman J
N Engl J Med; 1999 Dec; 341(24):1795-800. PubMed ID: 10588964
[TBL] [Abstract][Full Text] [Related]
17. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.
Patra P; Guha SK; Maji AK; Saha P; Ganguly S; Chakraborty A; Kundu PK; Sarker S; Ray K
Indian J Pharmacol; 2012; 44(4):500-3. PubMed ID: 23087513
[TBL] [Abstract][Full Text] [Related]
19. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
20. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]